Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | FABP7 | O15540 | 1/20 | 0.36 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.36 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.34 |
| ▸ | MDM4 | O15151 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | TLR2 | O60603 | 2/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | CASP3 | P42574 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17751582 | 1.00 | KMT2A (0.44) | KMT2AFABP7FABP5MDM2MDM4 | |
| SCHEMBL18177182 | 0.99 | KMT2A (0.44) | KMT2AFABP7FABP5MDM2MDM4 | |
| SCHEMBL25657687 | 0.92 | KMT2A (0.48) | KMT2AFABP7FABP5MDM2MDM4 | |
| SCHEMBL17751637 | 0.89 | KMT2A (0.56) | KMT2AFABP7FABP5MDM2MDM4 | |
| SCHEMBL17751714 | 0.89 | KMT2A (0.56) | KMT2AFABP7FABP5MDM2MDM4 | |
| SCHEMBL17751719 | 0.89 | KMT2A (0.56) | KMT2AFABP7FABP5MDM2MDM4 | |
| SCHEMBL13254138 | 0.89 | KMT2A (0.56) | KMT2AFABP7FABP5MDM2MDM4 | |
| SCHEMBL17751718 | 0.89 | KMT2A (0.56) | KMT2AFABP7FABP5MDM2MDM4 | |
| SCHEMBL17751724 | 0.89 | KMT2A (0.56) | KMT2AFABP7FABP5MDM2MDM4 | |
| SCHEMBL17751716 | 0.89 | KMT2A (0.56) | KMT2AFABP7FABP5MDM2MDM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230226193-A1 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS | Arrowhead Pharmaceuticals, Inc. | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226193-A1 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS | CPT1B, MUSK, MYLK2 | KMT2A 1603/4885FABP7 100/4885FABP5 304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.